NCT05699135View on ClinicalTrials.gov

A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer

TerminatedOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions

Urinary Bladder NeoplasmsBladder CancerBladder TumorsUrothelial Carcinoma

Interventions

DRUG

Avelumab first-line maintenance

Patients with LA/mUC who following 4-6 cycles platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight, intravenously administered over 60 minutes every 2 weeks

Trial Locations (1)

L5K2L3

Bayshore Specialty Rx, Mississauga